Company Filing History:
Years Active: 2013
Title: Innovations of Boris Klementiev in Peptide Research
Introduction
Boris Klementiev is a notable inventor based in Birkerød, Denmark. He has made significant contributions to the field of peptide research, particularly in the development of compounds that interact with neural cell adhesion molecules.
Latest Patents
Klementiev holds a patent for "Peptides derived from NCAM (FGLs)." This invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,11 module of neural cell adhesion molecule (NCAM). These compounds are capable of interacting with fibroblast growth factor receptors (FGFR), which can induce differentiation, modulate proliferation, stimulate regeneration, and enhance neuronal plasticity or survival of cells. Furthermore, the compounds can be utilized in the production of medicaments for treating conditions and diseases where NCAM or FGFR play a prominent role. He has 1 patent to his name.
Career Highlights
Boris Klementiev is currently associated with Enkam Pharmaceuticals A/S, where he continues to advance his research in the field of biomedicine. His work focuses on the therapeutic potential of peptides in various medical applications.
Collaborations
Klementiev collaborates with notable colleagues, including Vladimir Berezin and Elisabeth Bock, who contribute to his research endeavors.
Conclusion
Boris Klementiev's innovative work in peptide research highlights the potential of NCAM-derived compounds in medical treatments. His contributions are paving the way for advancements in therapeutic applications.